First Time Loading...

DermTech Inc
NASDAQ:DMTK

Watchlist Manager
DermTech Inc Logo
DermTech Inc
NASDAQ:DMTK
Watchlist
Price: 0.702 USD -0.99% Market Closed
Updated: Mar 29, 2024

Intrinsic Value

DMTK's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

DermTech, Inc. is a genomics company in dermatology, which engages in the development and sale of products for the diagnosis and treatment of skin diseases. [ Read More ]

The intrinsic value of one DMTK stock under the Base Case scenario is 4.744 USD. Compared to the current market price of 0.702 USD, DermTech Inc is Undervalued by 85%.

Key Points:
DMTK Intrinsic Value
Base Case
4.744 USD
Undervaluation 85%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
DermTech Inc

Backtest DMTK Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling DMTK stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Financials

Balance Sheet Decomposition
DermTech Inc

Current Assets 61.8m
Cash & Short-Term Investments 55.9m
Receivables 2.6m
Other Current Assets 3.3m
Non-Current Assets 60.2m
PP&E 56.7m
Other Non-Current Assets 3.5m
Current Liabilities 13.4m
Accounts Payable 1.5m
Accrued Liabilities 11.8m
Other Current Liabilities 213k
Non-Current Liabilities 51.3m
Long-Term Debt 38k
Other Non-Current Liabilities 51.3m
Efficiency

Earnings Waterfall
DermTech Inc

Revenue
15.3m USD
Cost of Revenue
-15m USD
Gross Profit
276k USD
Operating Expenses
-104m USD
Operating Income
-103.7m USD
Other Expenses
2.9m USD
Net Income
-100.9m USD

Free Cash Flow Analysis
DermTech Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

DMTK Profitability Score
Profitability Due Diligence

DermTech Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
ROIC is Increasing
Positive 1-Year Revenue Growth
Positive Gross Profit
23/100
Profitability
Score

DermTech Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

DMTK Solvency Score
Solvency Due Diligence

DermTech Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Low D/E
Long-Term Solvency
51/100
Solvency
Score

DermTech Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

DMTK Price Targets Summary
DermTech Inc

Wall Street analysts forecast DMTK stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for DMTK is 2.856 USD with a low forecast of 1.515 USD and a high forecast of 4.2 USD.

Lowest
Price Target
1.515 USD
116% Upside
Average
Price Target
2.856 USD
307% Upside
Highest
Price Target
4.2 USD
498% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

DMTK Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

DMTK Price
DermTech Inc

1M 1M
-45%
6M 6M
-51%
1Y 1Y
-81%
3Y 3Y
-98%
5Y 5Y
-97%
10Y 10Y
-96%
Annual Price Range
0.702
52w Low
0.65
52w High
4.58
Price Metrics
Average Annual Return -5.62%
Standard Deviation of Annual Returns 106.48%
Max Drawdown -99%
Shares Statistics
Market Capitalization 24.2m USD
Shares Outstanding 34 623 400
Percentage of Shares Shorted 9.38%

DMTK Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

DermTech Inc Logo
DermTech Inc

Country

United States of America

Industry

Biotechnology

Market Cap

24.2m USD

Dividend Yield

0%

Description

DermTech, Inc. is a genomics company in dermatology, which engages in the development and sale of products for the diagnosis and treatment of skin diseases. The company is headquartered in La Jolla, California and currently employs 255 full-time employees. The company went IPO on 2017-06-20. The firm is focused on developing and marketing non-invasive genomics tests to aid in the diagnosis and management of various skin conditions, including skin cancer, inflammatory diseases, and aging-related conditions. The company provides the Pigmented Lesion Assay (PLA), which is a gene expression test that enables early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The firm offers the Nevome test, which is an adjunctive reflex test for the PLA and is used with histopathology to identify additional risk factors for melanoma and confirm the diagnosis. Its Adhesive Skin Sample Collection Kit offers properties of the adhesive and a collection of informative cellular materials for its PLA. The Company’s Telemedicine Option for the PLA is the provision of health-related services and information through electronic information and telecommunication technologies.

Contact

CALIFORNIA
La Jolla
11099 N Torrey Pines Rd Ste 100
+18584504222.0
https://dermtech.com/

IPO

2017-06-20

Employees

255

Officers

CFO, Treasurer & Secretary
Mr. Kevin Sun M.B.A.
General Counsel
Mr. Ray Akhavan Esq., J.D.
President, CEO & Director
Mr. Bret Christensen
Chief Information Officer
Mr. William W. Zondler
Senior Director of Investor Relations
Mr. Steve E. Kunszabo
Chief Compliance Officer
Ms. Jennifer Eilemberg
Show More
Chief Medical Affairs Officer
Dr. Burkhard Jansen M.D.
Senior Vice President of Payer Access
Mr. Daniel Visage
Chief Medical Officer
Dr. Loren Clarke M.D.
Senior Vice President of Research & Development
Dr. Steven Stone Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one DMTK stock?

The intrinsic value of one DMTK stock under the Base Case scenario is 4.744 USD.

Is DMTK stock undervalued or overvalued?

Compared to the current market price of 0.702 USD, DermTech Inc is Undervalued by 85%.